Iovance Biotherapeutics (IOVA) Long-Term Deferred Tax (2012 - 2013)
Iovance Biotherapeutics (IOVA) posted quarterly Long-Term Deferred Tax of $3.7 million for Q4 2013, down 47.12% year-over-year from $7.0 million in Q4 2012, and down 47.12% quarter-over-quarter from $7.0 million in Q4 2012.
Iovance Biotherapeutics (IOVA) Long-Term Deferred Tax (2012 - 2013) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Long-Term Deferred Tax for 2 consecutive years, with $3.7 million the latest figure, recorded in Q4 2013.
- In Q4 2013, Long-Term Deferred Tax fell 47.12% year-over-year to $3.7 million; the TTM figure through Dec 2013 stood at $3.7 million (down 47.12% YoY), while the FY2013 annual figure was $3.7 million, down 47.12% from the prior year.
- Long-Term Deferred Tax eased to $3.7 million in Q4 2013 per IOVA's latest filing, from $7.0 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $7.0 million in Q4 2012 and bottomed at $3.7 million in Q4 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2013 | 3.68 Mn |
| Dec 31, 2012 | 6.96 Mn |